Kauliv

Teriparatide, the active ingredient in Kauliv, is a parathyroid hormone analog presented as a subcutaneous injection for subcutaneous use. It treats osteoporosis in postmenopausal women, men at high risk of fracture, and glucocorticoid‑induced osteoporosis. GNH USA supplies Kauliv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Teriparatide is used as an anabolic therapy for bone loss conditions. - Osteoporosis in postmenopausal women: improves bone mineral density and reduces fracture risk. - Osteoporosis in men at high risk of fracture: stimulates bone formation to strengthen skeletal integrity. - Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss by enhancing osteoblast activity.

Teriparatide may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Dizziness: occasional light‑headedness. - Injection‑site reactions: redness, swelling, or pain at the administration site. - Hypercalcemia: mild elevation of serum calcium levels.

Serious or Rare Side Effects: - Osteosarcoma: extremely rare malignant bone tumor reported in long‑term animal studies. - Severe hypercalcemia: marked increase in calcium requiring medical intervention. - Hypotension: significant drop in blood pressure after injection. - Anaphylactic reaction: acute allergic response with airway compromise.

Before initiating teriparatide therapy, consider the following precautions. - Hypercalcemia: avoid use in patients with elevated serum calcium. - Bone malignancy: contraindicated in individuals with active bone cancers or a history of osteosarcoma. - Prior radiation therapy: assess risk if the patient has received extensive skeletal radiation. - Renal impairment: monitor kidney function and calcium levels regularly. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide can interact with other agents that affect calcium metabolism.

Major Interactions (Avoid): - Calcium supplements or high‑dose vitamin D: may cause excessive hypercalcemia. - Other parathyroid hormone analogs: additive effects on calcium levels. - Bisphosphonates administered concurrently: may blunt anabolic response.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase calcium excretion, requiring monitoring of serum calcium. - Glucocorticoids: may reduce bone‑forming efficacy, necessitating dose adjustment. - Estrogen therapy: potential synergistic effect on bone turnover, monitor bone markers.